The odds here were brutal from the first shuffle: relapsed AML after a donor stem cell transplant is the kind of clinical poker game where the house usually wins, the chips are on fire, and somebody in the back is yelling "what if we engineered the security team?" That, more or less, is where VCAR33 walks onto the stage.
This study looked at a donor-derived CAR T-cell therapy called VCAR33 for people with acute myeloid leukemia (AML) or related myelodysplastic syndrome who had come back after an allogeneic hematopoietic cell transplant. Translation: patients had already been through one of the biggest weapons in blood cancer treatment, and the leukemia still found a way to sneak back in like a movie villain who definitely should have stayed dead after part two.
Meet the Target: CD33, the Name Tag on a Lot of AML Cells
AML is a fast-moving blood cancer where immature myeloid cells pile up in the bone marrow and crowd out normal blood production. It is less "one bad lump" and more "your bone marrow's group project has gone fully feral." Many AML cells carry a surface marker called CD33, which makes it an appealing target for therapy.[^wiki1][^wiki2]
CAR T cells are immune cells reprogrammed to recognize a target and attack it. They have already had their superhero-franchise moment in some B-cell cancers. AML, however, has been the annoying reboot nobody can quite nail. Why? Because the targets on AML cells often also show up on healthy blood-forming cells. So the trick is not just "find the bad guy." It is "find the bad guy without blowing up the entire building." Reviews over the last few years keep circling the same headaches: antigen overlap, disease heterogeneity, weak persistence, and the generally rude behavior of AML biology.[^ref2][^ref3][^ref4]
What This Trial Actually Did
In this phase 1/2 study, researchers treated 15 adults with relapsed or measurable residual disease-positive CD33+ AML/MDS after allogeneic transplant. The CAR T cells were donor-derived, meaning they came from the original stem cell donor rather than being made from the patient's own T cells. That is an interesting twist, because after transplant, the donor immune system is already part of the whole anti-leukemia strategy. VCAR33 is basically the donor immune system getting a sequel, better costume, and more specific lines.
Patients were split by disease burden. Seven had more overt marrow disease, and eight had lower-level disease. The study stopped before the highest planned dose was reached, for non-safety reasons, so this is very much an early read and not the season finale.
The Safety Story: Spicy, But Not Chaos
The most common side effect was cytokine release syndrome, seen in 93.3% of patients, but all cases were below grade 3. That sounds alarming until you remember CAR T trials often come with this territory. Think of it as the immune system pulling the fire alarm while rushing the stage. Neurotoxicity happened in 26.7%, including one severe case, and one patient had grade 3 acute graft-versus-host disease within 28 days.[^ref1]
So no, this was not side-effect-free. In AML cell therapy, "acceptable safety" does not mean "a relaxing spa weekend." It means the toxicity looked serious but manageable enough to justify continued interest in a setting where the alternatives are often grim.
The Efficacy Story: Small Signal, Real Signal
The overall response rate was 20%. Two patients with higher disease burden achieved complete remission with incomplete count recovery, and one patient with lower disease burden achieved MRD clearance.[^ref1]
That is not a mic-drop cure rate. Nobody should pretend otherwise. But in this setting, even a modest signal gets attention, because relapse after allogeneic transplant remains one of the toughest corners in leukemia care. Reviews and clinical perspectives still describe post-transplant AML relapse as a high-mortality problem with limited durable options.[^ref5][^ref6] If your standard menu is "more chemo, donor lymphocyte infusion, maybe another transplant, maybe not enough time," a therapy that shows early anti-leukemia activity without instantly detonating the marrow deserves a long look.
Why This Is Interesting Beyond the Headline
The big idea here is not just "CAR T for AML." It is CAR T for AML after transplant, using donor-derived cells, aimed at long-term surveillance. That is a pretty clever concept. Instead of waiting for leukemia to fully kick the door down, you try to post better guards at the entrance.
And yes, AML still behaves like the final boss who has multiple forms, weird armor, and an unfair healing mechanic. CD33 is a logical target, but not a perfect one. Researchers are already exploring ways around that problem, including dual-target CARs, better construct design, and even gene-edited transplant strategies that might let doctors target CD33 more aggressively while sparing healthy blood formation.[^ref2][^ref3][^ref7]
So this study does not prove we have cracked AML CAR T therapy. It does suggest the field is no longer just waving mood boards around and saying "someday." There is now an actual clinical signal, in actual post-transplant patients, in an area where medicine has badly needed a plot twist.
If these results hold up in larger studies, the real-world impact could be significant: more precise post-transplant immune control, earlier interception of relapse, and maybe fewer patients forced into the medical equivalent of rebooting the same doomed franchise for a third time.
References
[^wiki1]: Wikipedia contributors. Acute myeloid leukemia. Wikipedia. https://en.wikipedia.org/wiki/Acute_myeloid_leukemia
[^wiki2]: Wikipedia contributors. CD33. Wikipedia. https://en.wikipedia.org/wiki/CD33
[^ref1]: Mushtaq MU, DiPersio JF, Azzi J, et al. A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. Blood. 2025. DOI: https://doi.org/10.1182/blood.2025031053
[^ref2]: Heuser M, Roddie C, Kayser S. Chimeric antigen receptor T cells for acute myeloid leukemia. Eur J Haematol. 2023. DOI: https://doi.org/10.1111/ejh.14047
[^ref3]: Epperly R, Gottschalk S, Velasquez MP. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer. 2021;9:e003149. DOI: https://doi.org/10.1136/jitc-2021-003149
[^ref4]: Masetti R, et al. CAR T-cell therapy in acute myeloid leukemia. Stem Cell Res Ther. 2024. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11463564/
[^ref5]: Crippa MC, de Fabritiis P. Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation. Biomedicines. 2024;12(8):1721. DOI: https://doi.org/10.3390/biomedicines12081721
[^ref6]: Scott BL, Pasquini MC, Logan BR, et al. Treatment of AML Relapse After Allo-HCT. Front Oncol. 2021;11:812207. DOI: https://doi.org/10.3389/fonc.2021.812207
[^ref7]: Scherer J, et al. Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). N Engl J Med. 2025. PubMed: https://pubmed.ncbi.nlm.nih.gov/41129765/
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.